Antigen Express provides update on ongoing AE37 Phase 2 trial in breast cancer
 

Generex Biotechnology Corporation announced today that the Company's wholly-owned subsidiary Antigen Express, Inc. presented an update of the ongoing Phase 2 trial with an off-the-shelf immunotherapeutic cancer vaccine, AE37, in patients with breast cancer at Cambridge Healthtech Institute's Sixth Annual ImVacS: The Immunotherapeutics and Vaccine Summit held August 16-18, 2011 in Cambridge, MA.

More...